Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scripts

Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.

“The addition of Tyrvaya Nasal Spray to Express Scripts’ formulary moves us forward with our plan to optimize coverage and ensure patients and eye care professionals have access to the first and only nasal spray approved for the signs and symptoms of dry eye disease,” John Snisarenko, MBA, chief commercial officer, Oyster Point Pharma, said in a company news release. “At Oyster Point Pharma, we remain committed to optimizing access for people suffering with dry eye disease, a chronic condition that impacts an estimated 38 million people in the U.S.”
   
On October 15, 2021, the FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Tyrvaya became commercially available at pharmacies and for home delivery in November 2021. Tyrvaya is believed to activate the trigeminal parasympathetic pathway, resulting in increased basal tear film production as a treatment for dry eye disease.